Use the pattern recognition workspace to apply Short Line Candle recognition and other studies to Tyra Biosciences. The focus on pattern recognition signals tied to momentum and continuation helps organize trend, volatility, and risk context for Tyra Biosciences.
The output start index for this execution was ten with a total number of output elements of fifty-one. The function generated a total of four valid pattern recognition events for the selected time horizon. The Short Line Candle pattern describes signals for either bullish or bearish trend during either reversal or continuation condition of Tyra Biosciences.
Tyra Biosciences Technical Analysis Modules
Most technical analysis of Tyra Biosciences help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Tyra from various momentum indicators to cycle indicators. When you analyze Tyra charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California. Tyra Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 25 people. As a mid-cap equity, Tyra Biosciences is reviewed for growth durability, margin stability, and risk discipline. Current metrics include P/B of 7.59. Tyra Biosciences has a market cap of 1.97 B, ROE of -39.83%.
Methodology
Unless otherwise specified, financial data for Tyra Biosciences is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Tyra (USA Stocks:TYRA) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Inputs are aggregated from public filings and market reference sources and public institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Certain values may not reflect real-time changes. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Tyra Biosciences is covered by 11 analysts. 5 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Evercore ISI, Morgan Stanley, BMO Capital Markets, Oppenheimer & Co., Guggenheim Securities, HSBC Global Research, Raymond James, Bernstein Research, among others. Updates may occur throughout the day.
Tracking Tyra Biosciences inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Generate Optimal Portfolios
Align your risk and return expectations
By capturing risk tolerance and investment horizon, Macroaxis optimization evaluates acceptable risk for target return profiles. The process summarizes how much risk can be taken for a given return goal.
Reviewing Tyra Biosciences commonly begins with financial statements and performance trends. Financial ratios provide context for profitability, efficiency, and growth trends. Selected reports below provide context for Tyra Stock:
Tyra Biosciences has a market cap of 1.97 B, ROE of -39.83%. See World Market Map for portfolio-level analysis. This suggests a position in Tyra Biosciences within the allocation view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
Our How to Buy Tyra Stock guide explains the steps to invest in Tyra Biosciences stock.Analysis related to Tyra Biosciences should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Earnings Share
-2.01
Return On Assets
-0.26
Return On Equity
-0.40
Investors evaluate Tyra Biosciences using market value and book value, each describing different facets of the business. Tyra Biosciences' market capitalization is 1.97 B. With a P/B ratio of 7.59, the market values Tyra Biosciences well above its book equity. Enterprise value stands at 1.72 B. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
The concept of value for Tyra Biosciences differs from its quoted price, since each reflects a different lens. For Tyra Biosciences, key inputs include a P/B ratio of 7.59, and ROE of -39.83%. Trading price represents the transaction level agreed by market participants.